Combined modality therapy for early Hodgkin's disease: Heterogeneity in Australasian clinical practice

Australasian Radiology

Volumn 41, Issue 3, 1997, Pages 281-287

  Roos, Daniel ^a   O'Brien, Peter ^b  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b NEWCASTLE MATER HOSPITAL   (Australia)

Author keywords

Combined modality therapy; Continuing medical education; Hodgkin's disease; Radiation dose

Indexed keywords

BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; GALLIUM; METHOTREXATE; MITOXANTRONE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; ARTICLE; BIOPSY; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTINUING EDUCATION; FEMALE; HODGKIN DISEASE; HUMAN; LYMPHADENOPATHY; MALE; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; RADIATION DOSE;

EID: 0030876883     PISSN: 00048461     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1673.1997.tb00674.x     Document Type: Article

References (34)

1. Kaplan HS. Evidence for a tumoricidal dose level in radiotherapy of Hodgkin's disease. Cancer Res. 1966; 26: 1221-4.
2. Kaplan HS. Hodgkin's disease, 2nd edn. Harvard University Press, Cambridge, MA, 1980.
3. Fletcher GH, Shukovsky LJ. The interplay of radio-curability and tolerance in the irradiation of human cancers. J. Radiol. Electrol. 1975; 56: 383-400.
4. Vijayakumar S, Myrianthopoulos LC. An updated dose-response analysis in Hodgkin's disease. Radiother. Oncol. 1992; 24: 1-13.
5. Brincker H, Bentzen SM. A re-analysis of available dose-response and time-dose data in Hodgkin's disease. Radiother. Oncol. 1994; 30: 227-30.
6. Yelle L, Bergsagel D, Brown T et al. Combined modality therapy of HD: 10-year results of NCI Canada clinical trials group multicentre trial. J. Clin. Oncol. 1991; 9: 1983-93.
7. Loeffler M, Ruhl N, Hasenclever D et al. Irradiation with 20, 30 or 40 Gy is equally effective in non-bulky areas after two double cycles of COPP-ABVD polychemotherapy in intermediate stage Hodgkin's disease (Abstract). Blood 1994; 84 (Suppl. 1): A234.
8. Fabian CJ, Mansfield CM, Dahlberg S et al. Low-dose involved field RT after chemotherapy in advanced Hodgkin's disease (SWOG 7808). Ann. Intern. Med. 1994; 120: 903-12.
9. Dühmke E, Diehl V, Loeffler M et al. Randomized trial with early stage Hodgkin's disease testing 30 Gy vs 40 Gy extended field radiotherapy alone. Int. J. Radiat. Oncol. Biol. Phys. 1996; 36: 305-10.
10. Maity A, Goldwein JW, Lange B, D'Angio GJ. Comparison of high-dose and low-dose radiation with and without chemotherapy for children with Hodgkin's disease: An analysis of the experience at the Children's Hospital of Philadelphia and the Hospital of Pennsylvania. J. Clin. Oncol. 1992; 10: 929-36.
11. Donaldson SS, Link MP. Combined modality treatment with low-dose radiation and MOPP for children with Hodgkin's disease. J. Clin. Oncol. 1987; 5: 742-9.
12. Hunger SP, Link MP, Donaldson SS. ABVD/MOPP and low dose involved-field radiotherapy in paediatric Hodgkin's disease: The Stanford experience. J. Clin. Oncol. 1994; 12: 2160-6.
13. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late morbidity from heart disease after treatment of Hodgkin's disease. JAMA 1993; 270: 1949-55.
14. Coia LR, Hanks GE. Complications from large field intermediate dose infra-diaphragmatic radiation: An analysis of the Patterns of Care outcome studies for Hodgkin's disease and seminoma. Int. J. Radiat. Oncol. Biol. Phys. 1988; 15: 29-35.
15. Mah K, Keane TJ, Van Dyk J, Braban LE, Poon PY, Hao Y. Quantitative effect of combined chemotherapy and fractionated radiotherapy on the incidence of radiation induced lung damage: A prospective clinical study. Int. J. Radiat. Oncol. Biol. Phys. 1994; 28: 563-74.
16. Santaro A, Bonadonna G, Valagussa P et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease. Superiority of ABVD plus radiotherapy vs MOPP plus radiotherapy. J. Clin. Oncol. 1987; 5: 27-37.
17. Prosnitz LR. Hodgkin's disease: The right dose. Int. J. Radiat. Oncol. Biol. Phys. 1990; 19: 803-4.
18. Prosnitz LR, Roberts KB. Combined chemotherapy and radiotherapy for Hodgkin's disease. Oncology 1992; 6: 113-28.
19. Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: A preliminary report. J. Clin. Oncol. 1995; 13: 1080-8.
20. Behar RA, Horning JS, Hoppe RT. Hodgkin's disease with bulky mediastinal involvement: Effective management with combined modality therapy. Int. J. Radiat. Oncol. Biol. Phys. 1993; 25: 771-6.
21. Shore T, Nelson N, Weinerman B. A meta-analysis of stages I and II Hodgkin's disease. Cancer 1990; 65: 1155-60.
22. Pavlovsky S, Maschio M, Santarelli MT et al. Randomized trial of chemotherapy vs chemotherapy plus radiotherapy, for Stage I-II Hodgkin's disease. J. Natl Cancer Inst. 1988; 80: 1466-73.
23. Carde P, Hagenbeek A, Hayat M et al. Clinical staging vs laparotomy and combined modality with MOPP versus ABVD in early stage Hodgkin's disease. The H6 twin randomized trials from the European Organisation for Research and Treatment of Cancer Lymphoma Cooperative Group. J. Clin. Oncol. 1993; 11: 2258-72.
24. Canellos GP, Anderson JR, Propert KJ et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD or MOPP alternating with ABVD. N. Engl. J. Med. 1992; 327: 1478-84.
25. Horning SJ, Hoppe RT, Hancock SL, Rosenberg SA. Vinblastine, bleomycin, and methotrexate: An effective adjuvant in favourable Hodgkin's disease. J. Clin. Oncol. 1988; 6: 1822-31.
26. Rosenberg SA. The treatment of Hodgkin's disease. Ann. Oncol. 1994; 5 (Suppl. 2): 17-21.
27. Bates NP, Williams MV, Bessell EM, Vaughan-Hudson G, Vaughan-Hudson B. Efficacy and toxicity of vinblastine, bleomycin, and methotrexate with involved-field radiotherapy, in clinical stage IA and MA Hodgkin's disease: British National Lymphoma Investigation pilot study. J. Clin. Oncol. 1994; 12: 288-96.
28. Gobbi PG, Pieresca C, Corbella F et al. Vinblastine, bleomycin, and methotrexate (VBM) plus extended field radiotherapy in early, favourably presenting, clinically staged Hodgkin's disease (Abstract). Proc. Annu. Meet. Am. Soc. Clin. Oncol. 1995; 14: A1202.
29. Carde P, Noordijk EM, Hagenbeek A et al. Superiority of MOPP/ABV and EBVP in combination with involved field irradiation in unfavourable clinical stage I-II Hodgkin's disease: The EORTC-GPMC H7-U randomized trial (Abstract). Proc. Annu. Meet. Am. Soc. Clin. Oncol. 1993; 12: A1222.
30. King SC, Reiman RJ, Prosnitz LR. Prognostic importance of restaging gallium scans following induction chemotherapy for advanced Hodgkin's disease. J. Clin. Oncol. 1994; 12: 306-11.
31. Goldsmith GH. Gallium scans for residual Hodgkin's disease (Letter). J. Clin. Oncol. 1994; 12: 1336.
32. Karimjee S, Brada M, Husband J, McCready VR. A comparison of gallium-67 single photon emission computed tomography and computed tomography in mediastinal Hodgkin's disease. Eur. J. Cancer 1992; 28A: 1856-7.
33. Wylie BR, Southee AE, Joshua DE, McLaughlin AF et al. Gallium scanning in the management of mediastinal Hodgkin's disease. Eur. J. Haematol. 1989; 42: 344-7.
34. Colonna P, Jais J-P, Desablens B et al. Mediastinal tumour size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: Ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients. J. Clin. Oncol. 1996; 14: 1928-35.